Status:

RECRUITING

MSC Exosome Therapy for Post-Preeclampsia Endothelial Dysfunction

Lead Sponsor:

Universitas Padjadjaran

Collaborating Sponsors:

Dr. Hasan Sadikin General Hospital, Bandung, Indonesia

Dr Cipto Mangunkusumo General Hospital

Conditions:

Preeclampsia

Postpartum

Eligibility:

FEMALE

18-50 years

Phase:

PHASE1

PHASE2

Brief Summary

\--- Why Is This Study Being Done? Women who have preeclampsia during pregnancy face a much higher risk of heart disease later in life. Preeclampsia is a serious pregnancy condition that causes high...

Detailed Description

\--- Background and Rationale Preeclampsia affects 3-5% of pregnancies globally and represents a severe pregnancy-specific syndrome characterized by widespread maternal endothelial dysfunction. The ...

Eligibility Criteria

Inclusion

  • Postpartum
  • Confirmed diagnosis of preeclampsia in the last pregnancy
  • Postpartum period of first week and second week
  • Able to provide informed consent

Exclusion

  • History of chronic hypertension prior to pregnancy
  • Major cardiovascular disease history
  • Active systemic infection
  • Endothelial Injury history
  • Active smoking status including vape, alcohol, drug addiction.

Key Trial Info

Start Date :

July 1 2024

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

September 1 2026

Estimated Enrollment :

80 Patients enrolled

Trial Details

Trial ID

NCT07183384

Start Date

July 1 2024

End Date

September 1 2026

Last Update

September 19 2025

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Dr. Hasan Sadikin Central General Hospital

Bandung, West Java, Indonesia, 40161

MSC Exosome Therapy for Post-Preeclampsia Endothelial Dysfunction | DecenTrialz